HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 03-29-2004, 06:52 AM   #1
Paul
Guest
 
Posts: n/a
Transgenomic Inc. (Nasdaq: TBIO - News) announced today that during the American Association of Cancer Research annual meeting currently underway in Orlando several of its customers from major research institutions worldwide will present results in which the Company's WAVE System has played an important role. Specific scientific applications represented among these presentations include mutation detection -- both scanning and scoring methodologies -- as well as analysis of DNA methylation microsatellite instability and loss of heterozygosity. This body of work encompasses research involving a variety of different cancers including colorectal breast and ovarian lung bladder gastric and others.

Stan Lilleberg Ph.D. Transgenomic's director of Translational and Clinical Research Services pointed out that the WAVE System is being used in the field for a broadening set of applications.

The Company has also continued to build on the WAVE platform's historical strengths pushing further the limits of analytical sensitivity in detecting low-abundance mutations. "We are presenting data at this meeting that demonstrates the ability of our WAVE HS System to facilitate detection of mutations in small amounts of tumor-derived DNA found in the bloodstream of patients with solid tumors. A number of the genetic alterations detected with the WAVE HS were not detectable using various traditional approaches. We believe these results have potential implications for our partners in early cancer detection and/or novel post-therapy monitoring strategies."

Collin D'Silva Transgenomic's CEO commented "Historically the WAVE System has proven highly effective in scanning or scoring for low-abundance genetic variation which is particularly valuable for the analysis of somatic mutations that may arise during the course of cancer progression or in association with development of drug resistance."

  Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 01:51 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter